Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug
Cleavage of SDF-1 by DPP-4 results in loss of activity (65), and consistent with this, DPP-4 inhibition in humans has been associated with enhancement of some effects which are associated with SDF-1 [increased levels of circulating endothelial progenitor cells (66) and increased distal tube sodium excretion (64)]
As such, the skin on your feet may appear saggy
Key Takeaway: While chest pain is not a standard side effect of semaglutide, it should never be ignored, as it can signal a rare complication or a separate underlying health issue
Youve got high protein, high fiberall under the halo of being healthier, Caliendo says
